Stock selection in the information technology and financials sectors contributed to the relative performance of the fund.

AbbVie has delivered strong returns and dividend growth, with solid prospects but notable risks creating near-term ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This ...

Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term ...

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...

In late June of this year, biopharma giant AbbVie ($ABBV) struck a definitive $2.1 billion deal to acquire Capstan ...

Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite ...

A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a ...

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). | For the second time ...

An official report on August 20, 2025 reveals Representative Ritchie Torres's recent purchase of AbbVie ABBV +0.90% Get Free Report stock, valued between $78,078 and $1,170,000. The transaction took ...

AbbVie on Thursday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in patients with severe forms of the disease that causes sudden hair loss met its primary endpoint of 80% or more ...